Court Can't Block Nonfinal Compounding Policy, FDA Says
By Dani Kass · September 4, 2018, 5:47 PM EDT
Par Pharmaceutical is being premature by asking a D.C. federal court to enjoin a nonfinal policy regarding whether drugs like Par's blood pressure medication vasopressin can be compounded by outside companies,...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login